Prakruti R Pali has increased their shareholding in Astton Pharmaceuticals Limited from 2.51% to 5.33%. The acquisition, which involved 2,40,000 shares, was completed through an open market purchase on August 27, 2026. This move represents a substantial increase in voting rights, potentially impacting the control and strategic direction of the target company.
Acquisition Details
Prakruti R Pali, acting as the acquirer, has completed a transaction that significantly alters their stake in Astton Pharmaceuticals Limited. Prior to this acquisition, the acquirer held 2.14 lakh shares, representing 2.51% of the total voting capital. The transaction involved the acquisition of an additional 2,40,000 shares.
Post-Acquisition Holding
Following the acquisition, the total number of shares held by Prakruti R Pali in Astton Pharmaceuticals Limited stands at 4,54,000 shares. This brings their total holding to 5.33% of the company’s equity share capital. The acquisition was made through the open market and was fully paid up, with the transaction date recorded as August 27, 2026.
Capital Structure Impact
Before the acquisition, Astton Pharmaceuticals Limited had an equity share capital of 2,14,000 equity shares. Post-acquisition, this has increased to 4,54,000 equity shares. The total diluted share/voting capital of the Target Company after the said acquisition also stands at 4,54,000 equity shares, indicating no dilution from other instruments at this stage.
Source: BSE
